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Summary  Since  the  ﬁrst  transcatheter  implantation  of  a  pulmonary  valve  in  2000  in  a  twelve
year-old boy  with  a  dysfunctional  right  ventricle  to  pulmonary  artery  conduit  by  Philip  Bonho-
®effer and  Younes  Boudjemline,  the  Melody valve  has  become  worldwide  used.  It  represents  an
replacement; efﬁcient alternative  to  open-heart  surgery.  We  aimed  in  this  comprehensive  review  to  describe
Abbreviations: CP, Cheatham-Platinum; LV, left ventricle/ventricular; PPVI, percutaneous pulmonary valve implantation; RV, right
ventricle/ventricular; RVOT, right ventricular outﬂow tract; RV-PA, right ventricle to pulmonary artery; TOF, tetralogy of Fallot.
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the  current  indications  of  percutaneous  pulmonary  valve  implantation,  the  devices  currently
used and  the  clinical  results.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Depuis  la  première  implantation  percutanée  d’une  valve  pulmonaire  en  2000  chez  un
garc¸on de  12  ans  avec  un  conduit  défaillant  entre  le  ventricule  droit  et  l’artère  pulmonaire,  par
Philip Bonhoeffer  et  Younes  Boudjemline,  la  valve  Melody® est  devenue  d’utilisation  courante
dans de  nombreux  pays.  C’est  une  alternative  efﬁcace  à  la  chirurgie  conventionnelle  à  cœur
ouvert. L’objectif  de  cette  revue  non  systématisée  est  de  décrire  les  indications  actuelles
du remplacement  pulmonaire  percutané,  les  prothèses  actuellement  utilisées  et  les  résultats
cliniques.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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istorical background
ercutaneous  pulmonary  valve  implantation  (PPVI)  is  a
ajor  advance  in  the  interventional  treatment  of  congen-
tal  heart  diseases.  Transcatheter  relief  of  pulmonary  valvar
tenosis  was  ﬁrst  performed  in  1953  by  balloon  angioplasty
1].  Since  the  development  of  open-heart  surgery  in  the
ate  1950s  [2],  treatment  of  pulmonary  valve  or  right  ven-
ricular  to  pulmonary  artery  conduit  (RVPA)  regurgitation
as  entirely  surgical.  Need  for  repeated  surgeries  in  high-
isk  patients  yield  the  need  for  a  transcatheter  solution.
he  ﬁrst  percutaneous  transcatheter  implanted  valve  was
escribed  by  Davies  et  al.,  in  1965  to  treat  experimen-
ally  induced  aortic  regurgitation  in  dogs  [3].  However,  it
s  not  until  1992  that  Andersen  et  al.,  further  reported
he  successful  delivery  of  a  catheter-mounted,  balloon-
xpandable  stent  valve  in  the  aortic  position  in  pigs  [4].
he  same  year,  a  prosthetic  caged-ball  aortic  valve  was
lso  successfully  deployed  percutaneously  in  dogs  by  Pavc-
ik  et  al.  [5].  The  ﬁrst  transcatheter  pulmonary  valve  was
eveloped  by  Philipp  Bonhoeffer  and  Younes  Boudjemline
n  the  late  1990s.  A  valved  segment  of  a  bovine  jugular
ein  was  sewed  into  a  balloon-expandable  vascular  stent.
ranscatheter  pulmonary  valve  replacement  was  successful
n  animals  [6].  Soon  after,  the  ﬁrst  human  transcatheter
ardiac  valve  replacement  was  successfully  reported  in  a
welve  year-old  boy  with  a  dysfunctional  RVPA  conduit  [7].
edtronic  inc.  further  conducted  the  in-vitro  testing  to
omplete  the  design  process  of  the  named  Melody® transcat-
eter  pulmonary  valve.  European  certiﬁcation  was  obtained
n  2006  as  well  as  Health  Canada  approval,  making  it  the  ﬁrst
ommercially  available  transcatheter  valve  in  the  world.  A
elody® valve  was  implanted  in  the  100th  patient  in  2005
v
c
e
and  in  the  1000th  patient  in  2009.  The  Melody® valve  was
pproved  for  use  in  the  United  States  of  America  in  2010.
ince  2000,  many  clinical  studies  have  reported  early  and
id-term  outcome  and  more  than  6000  valves  have  been
mplanted  worldwide  [8—19].  The  Edwards® valve  (Edwards
APIEN® pulmonic  transcatheter  heart  valve,  Edwards  Life-
cience,  Irvine,  CA,  USA)  was  initially  used  for  transcatheter
ortic  valve  replacement  but  then  also  for  PPVI.  It  has
eached  CE  certiﬁcation  for  PPVI  in  2010.  First  implantation
as  performed  in  2006  in  USA  [20]  and  in  2010  in  Europe
21]. Clinical  results  in  the  ﬁrst  implanted  patients  have
ubsequently  been  published  [22—24].
oncept sustaining percutaneous
ulmonary valve implantation for the
anagement of congenital heart diseases
ncidence  of  congenital  heart  disease  is  approximately  8  out
f  1000  babies.  Around  20%  of  congenital  heart  diseases
nvolve  the  right  ventricle  outﬂow  tract  (RVOT)  and  the
ulmonary  valve.  Surgical  palliation  of  many  complex  con-
enital  heart  diseases,  including  tetralogy  of  Fallot  (TOF)
ith  pulmonary  atresia,  truncus  arteriosus,  some  forms  of
ransposition  of  the  great  arteries,  double-outlet  right  ven-
ricle,  Ross  surgery  for  aortic  valve  disease  and  others,
nvolves  interposition  of  a  conduit  between  the  right  ven-
ricle  and  the  pulmonary  artery  in  the  ﬁrst  months  of  life.
alved  conduits  are  composed  of  synthetic  material  or  non-
iable  homograft  or  xenograft  tissue.  Inability  to  follow  the
hild  growth,  mechanical  distortion  and  progressive  degen-
ration  lead  to  conduit  stenosis  over  time.  Regurgitation
ppears  with  degeneration  of  the  leaﬂets.  Other  congenital
d  av
p
r
d
e
f
l
I
v
g
R
m
f
v
t
s
a
v
p
o
d
d
a
v
>
[
P
f
i
i
u
M
a
f
g
T
f
e
t
H
C
M
E
T
i
t
M
TTranscatheter  pulmonary  valvulation:  Current  indications  an
heart  diseases  require  enlargement  of  the  RVOT  by  a  trans-
annular  patch  during  the  surgical  correction,  frequently
leading  to  pulmonary  valve  regurgitation  (TOF  with  pul-
monary  stenosis,  pulmonary  valve  agenesis  and  others).
Pulmonary  valve  regurgitation  may  complicate  transcat-
heter  dilation  of  pulmonary  valvar  stenosis  and  surgical
valvulotomy.  Isolated  congenital  pulmonary  regurgitation
remains  an  uncommon  cause  of  pulmonary  valve  replace-
ment  [25].
An  obstructed  RVOT  induces  a  pressure  overload  in  the
right  ventricle  (RV).  A  pulmonary  regurgitation  leads  to  a
volume  overload  and  thus  to  a  dilation  of  the  RV  [26].
Both  obstruction  and  regurgitation  may  be  combined.  These
lesions  are  often  long  well  tolerated  but  the  overload
of  the  RV  is  progressively  deleterious  for  the  right  ven-
tricular  function  [27]  and  then  ultimately  for  the  patient
[25,28,29].  Impaired  exercise  capacity,  atrial  and  ventricu-
lar  arrhythmias,  sudden  deaths  after  complete  repair  of  TOF
are  related  to  the  severity  of  the  pulmonary  regurgitation
and  lead  to  an  increased  overall  mortality  after  the  second
decade  [28,30,31].
Restoration  of  pulmonary  valve  competence  and  relief
of  RVOT  obstruction  are  beneﬁcial.  It  reduces  ventricular
overload,  increases  right  and  left  ventricular  performance
[32,33],  functional  ability  and  cardio-respiratory  exercise
performance  [33—35].  It  may  also  help  to  control  preexisting
atrial  and  ventricular  arrhythmias  in  TOF  patients  [36].
RVPA  conduit  obstruction  was  the  most  frequent  rea-
son  for  surgical  re-intervention  [37].  Transcatheter  relief
of  post-operative  RVOT  obstruction  was  early  attempted
with  balloon  angioplasty.  However,  ineffective  relief  was
observed  in  many  cases  due  to  elastic  recoil  and  non-
expandable  conduit.  Intravascular  stenting  further  helped
to  increase  efﬁciency  of  these  percutaneous  procedures  [38]
but  at  a  price  of  a  free  pulmonary  regurgitation  that  may
be  symptomatic  in  some  cases  [39].  PPVI  seemed  there-
fore  promising  to  treat  RVOT  obstruction  without  inducing
pulmonary  regurgitation  but  no  studies  are  available  to  com-
pare  the  outcome  of  both  strategies  (non  valved  stent  vs.
valved  stent).  Until  PPVI,  treatment  of  RVOT  regurgita-
tion  required  open-heart  surgery.  Despite  improved  surgical
technique  and  good  mid-term  outcome,  the  surgery  car-
ries  short-time  morbidity  in  these  patients  with  multiple
previous  procedures.  It  starts  again  the  conduit  duration
countdown.  Around  50%  of  conduits  still  require  replace-
ment  within  10  years  [37].  Second  and  subsequent  conduits
have  shorter  survival  than  the  original  implants  [37]. Less
procedural  morbidity  existing  with  PPVI  offered  a  new  solu-
tion  for  the  management  of  these  patients.  PPVI  allows
concomitantly  relief  of  RVOT  obstruction  and  regurgita-
tion,  maintaining  pulmonary  valve  competence  [13].  PPVI
restores  right  ventricular  load  within  normal  range.  An
early  improvement  of  biventricular  performance  is  observed
following  relief  of  RVOT  obstruction,  with  decrease  right
ventricular  volumes,  increased  right  and  left  ventricular
systolic  function  and  increased  cardiac  output  [19,33,40].
Relief  of  obstruction  also  improves  early  left  ventricular  ﬁll-
ing  properties.  This  improvement  is  not  only  related  to  the
increase  in  right  ventricular  forward  ﬂow  but  also  to  a more
favorable  ventricular  interaction  [41].  After  PPVI,  dyspnea
degree  decreases  and  exercise  tolerance  is  rapidly  improved
[19,33,40].  This  is  less  clear  in  case  of  PPVI  indicated  for
P
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ulmonary  regurgitation  without  RVOT  obstruction  and  is
elated  like  with  surgical  replacement  to  the  degree  of  RV
ilation  at  the  time  of  replacement  [19,40,42]. The  acute
ffects  of  PPVI  are  maintained  over  time  without  evidence
or  further  ventricular  remodeling  or  positive  functional  evo-
ution  beyond  the  early  post-operative  period  [42].
ndication for percutaneous pulmonary
alve  implantation, current ofﬁcial
uidelines
ecommendations  for  PPVI  match  those  for  surgical  pul-
onary  valve  replacement,  with  speciﬁcity  regarding
easibility  and  outcome  of  the  percutaneous  implanted
alves.
In  Europe,  the  European  society  guidelines  stipulate
hat  pulmonary  valve  replacement  should  be  performed  in
ymptomatic  patient  with  severe  pulmonary  regurgitation
nd/or  RVOT  obstruction  (Tricuspid  velocity  >  3.5  m/s,  right
entricular  systolic  pressure  >  60  mmHg).  In  asymptomatic
atients  with  severe  pulmonary  regurgitation  and/or  RVOT
bstruction,  PPVI  may  be  considered  if  there  is  an  objective
ecrease  in  exercise  capacity,  a  progressive  right  ventricular
ilation,  a  progressive  right  ventricular  systolic  dysfunction,
 progressive  tricuspid  regurgitation,  sustained  atrial  or
entricular  arrhythmias,  right  ventricular  systolic  pressure
 80  mmHg  or  peak  tricuspid  regurgitation  velocity  >  4.3  m/s
43].
In  France,  the  ‘‘Haute  Autorité  de  santé’’  stipulates  that
PVI  is  indicated  to  treat  RVPA  conduit  or  xenograft  dys-
unction,  with  a  minimal  internal  diameter  of  16  mm.  PPVI
n  a  native  RVOT  or  in  child  weighting  less  than  20  kg  is  not
ndicated  [44].
The  Food  and  drug  administration  instructions  for  use
nder  a  humanitarian  device  exemption  stipulate  that  the
elody® PPVI  is  indicated  in  the  management  of  pediatric
nd  adult  patients  with  the  existence  of  a full  circum-
erential  dysfunctional  RVOT  conduit  that  was  equal  to  or
reater  than  16  mm  in  diameter  when  originally  implanted.
he  dysfunctional  RVOT  conduit  is  retained  as  an  indication
or  PPVI  if  the  regurgitation  is  equal  to  or  greater  than  mod-
rate  and/or  if  the  mean  RVOT  gradient  is  equal  to  or  greater
han  to  35  mmHg.  The  scientiﬁc  statement  from  American
eart  Association  endorsed  this  recommendation  [45].
urrent devices
elody® transcatheter pulmonary valve and
nsemble® delivery system
he  Melody® valve  (Medtronic  Inc.,  Minneapolis,  MN,  USA)
s  the  ﬁrst  valve  inserted  percutaneously  in  humans.  It is
he  most  used  valve  in  the  world  in  pulmonary  position.
ost  of  the  available  data  for  PPVI  are  coming  from  its  use.
he  device  is  made  of  a  bovine  jugular  vein  valve  (Contegra
ulmonary  Valved  conduit,  Medtronic  Inc.,  Minneapolis,  MN,
SA)  sutured  within  a  Cheatham-Platinium  stent  (CP  stent,
uMED  Inc.,  Hopkinton,  NY)  (Fig.  1).  The  bovine  jugular  vein
s  different  from  the  surgical  implant.  It  is  trimmed  to  reduce
628  S. Hascoët  et  al.
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wigure 1. Melody® transcatheter pulmonary valve.
ts  thickness  before  suturing  in  the  vascular  stent.  Its  length
s  shorter  than  the  Contegra  and  equal  to  the  length  of  the
P  stent  (CP8Z34).
At the  moment,  there  is  only  one  size.  It  is  a  one-
ized  valve  of  18  mm  in  diameter  that  is  crimped  to  6mm
nd  balloon  expanded  from  18  to  22  mm  in  diameter.  The
ovine  jugular  vein  has  thin,  compliant  leaﬂets  with  deep
ommissures  that  provide  exceptional  coaptation  of  the
eaﬂets  at  various  internal  diameters.  It  opens  fully  and
lose  readily  with  a  minimum  of  pressure.  The  vein  tis-
ue  has  a  thickness  of  less  than  0.5  mm.  The  vein  segment
s  manually  sutured  to  the  stent  frame  at  every  stent
ode.  Complete  suture  lines  are  also  done  at  the  inﬂow
nd  outﬂow  part  of  the  stent.  The  CP  stent  has  a  closed-
ell  design  with  six  rows  of  circumferential  struts.  Each
ow  is  made  of  a  platinium-iridium  wire  that  is  welded  in
 zig  pattern  to  form  eight  crowns.  The  zig-to-zig  welds
re  gold-brazed  to  increase  their  strength.  The  stent  mea-
ures  3 mm  in  length  in  an  unexpanded  conﬁguration  and
6.2,  24.2  and  23  mm  when  implanted  at  18,  20  and  22  mm
espectively.  This  stent  was  chosen  by  Bonhoeffer  and  Boud-
emline  because  it  is  a  good  compromise  between  rigidity
or  the  radial  force  and  malleability  for  the  manual  crimp-
ng.  It  has  a  good  radio-opacity,  a  good  conformation,  is
asy  to  crimp  on  a  balloon  and  has  a foreshortening  to
 degree  that  does  not  distort  the  valve  leaﬂets.  The
®elody valve  manufacturing  follows  a  step-by-step  rigor-
us  process  and  testing  before  commercialization  [46].  As
 result,  less  than  5%  of  bovine  jugular  veins  are  avail-
ble  for  PPVI.  Because  of  availability  problem  with  the
l
b
u
aovine  jugular  vein,  Medtronic  is  introducing  a  new  Melody®
anufactured  with  a  16-mm  valve  that  would  works  for
atients  up  to  20-mm.  Its  introduction  is  programmed  for
urope  at  the  end  of  2014.
The  Melody® valve  is  implanted  through  a dedicated
elivery  system  (Ensemble ® Transcatheter  Delivery  Sys-
em,  Medtronic  Inc.,  Minneapolis,  MN,  USA).  It  consists
f  a  balloon-in-balloon  (BiB,  NuMED  Inc.,  Hopkinton,  NY)
atheter  delivery  system  with  a  retractable  sheath  that  cov-
rs  the  Melody® valve  once  it  is  crimped  over  the  balloon
Fig.  2).  The  BIB  balloon  allows  repositioning  during  the
alve  delivery  (Fig.  3).  The  outer  balloon  is  available  in  3
izes:  18  mm,  20  mm  and  22  mm  in  diameter.  The  thickness
f  the  valve  stent  assembly  is  approximately  1  mm  resulting
n  an  outer  diameter  of  2mm  more  than  the  diameter  of  the
elivery  balloon.  A  sheath  with  side  port  allows  ﬂushing  the
ystem  and  acts  as  a  homeostatic  sleeve  to  minimize  bleed-
ng  at  the  insertion  site.  The  outer  diameter  at  the  top  of
he  delivery  system  is  22  Fr  [46].
dwards SAPIEN® pulmonic transcatheter
eart valve and Retroﬂex® delivery system
he  Edwards® valve  (Edwards  SAPIEN® pulmonic  transcat-
eter  heart  valve,  Edwards  Lifescience,  Irvine,  CA,  USA)
as  introduced  later.  Results  with  this  device  remainimited.  It  is  made  of  a  radiopaque,  stainless  steel,
alloon-expandable  support  structure,  with  an  integrated,
nidirectional,  tri-leaﬂets  bovine  pericardium  valve  and
 polyethylene  terephthalate  fabric  cuff.  It  is  available
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in  23,  26  and  29-mm  in  diameter  (14.3  and  17.2  and
19.1  mm  in  height  respectively)  (Fig.  4).  The  valve  is  treated
according  to  the  Edwards  ThermaFix  process.  There  are
generations  of  valves.  The  Edwards  valve  is  implanted
through  the  Retroﬂex® delivery  system.  It  consists  of  bal-
loon  catheter  and  a  deﬂectable  guiding  catheter.  It  requires
either  a  22  Fr  or  a  24  Fr  (outer  diameter  28  Fr)  insertion
sheath  for  the  23  and  26  mm  valves  respectively.  A  man-
ual  crimping  tool  is  used  to  symmetrically  compress  the
valve  onto  the  30mm-balloon.  The  Edwards® valve  was  ini-
tially  introduced  for  transcatheter  aortic  valve  replacement
in  elderly  patients  with  degenerative  aortic  valve  stenosis.
Melody® valve  size  limits,  concerns  about  stent  fractures  and
s
b
s
Figure 3. The Melody® valve is manually crimped on the Ensemble® d
repositioning of the valve and then the outer balloon fully expands the Mndocarditis  encourage  some  physicians  to  successfully  use
he  Edwards  valve  in  the  pulmonary  position  [20—24,47,48].
he  results  in  the  ﬁrst  implanted  patients  seem  promising.
he  Edwards® valve  is  efﬁcient  and  safe  in  reducing  RVOT
ressure  gradient  and  restore  pulmonary  valve  competence.
ut  more  data  are  needed  particularly  regarding  long-term
utcome.  Some  operators  raised  concerns  about  asymmet-
ical  valve  expansion,  residual  pulmonary  regurgitation  and
evice  embolization  that  were  not  conﬁrmed  in  the  last
eries  [22,49].  The  Edwards® valve  is  currently  not  reim-
ursed  in  France  and  only  available  in  research  programs.
To  date  to  our  knowledge  only  one  single  center  retro-
pective  non-randomized  comparative  study  between  the
elivery system balloon. The inner balloon is inﬂated ﬁrst allowing
elody® valve.
630  S. Hascoët  et  al.
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pigure 4. Edwards SAPIEN® pulmonic valve.
elody® valve  and  the  Edwards® valve,  involving  30  patients
as  been  published  [50].  Short-term  outcome  was  good  and
imilar  regarding  RVOT  gradient  and  valve  function.  One
atient  from  the  Edwards® valve  group  had  valve  migration.
his  observation  was  also  observed  in  some  other  patients
24].  This  may  be  due  to  the  smaller  length  of  the  Edwards
alve,  long  length  of  the  balloon  catheter  and  a  less  poten-
ial  for  staged  repositioning  during  deployment  with  the
ingle  balloon  delivery  catheter.  Higher  peak  and  mean  gra-
ients  were  also  observed  with  the  Edwards® valve  during
ollow-up.  However,  if  this  observation  results  from  method-
logical  bias  or  from  valve  difference  remains  unclear,  data
re  not  sufﬁcient  to  date  to  compare  risk  speciﬁcities  within
he  2  valves.  However,  in  case  of  failed  implantation,  extra-
orporeal  Edwards  valve  retraction  is  not  possible  given  the
esign  of  the  retroﬂex® delivery  system  contrary  to  the
nsemble® system.
eneral implant considerations
perator
PVI  remains  a  long  and  challenging  procedure.  Success  rate
nd  risk  of  adverse  events  is  related  to  operator  experience
13].  In  France,  around  60  procedures  are  performed  every
ear.  Thus,  only  a  few  specialized  operators  are  experienced
r  have  been  certiﬁed  for  this  procedure  after  having  com-
leted  a  training  program.  A  minimum  of  5  PPVI  per  operator
er  year  is  recommended.  Life-threatening  adverse  events
lthough  rare,  may  require  rescue  surgery.  Thus,  in  France,
PVI  are  only  performed  in  centers  specialized  in  congenital
eart  diseases  with  a  surgery  platform  (M3C  network)  with
 surgeon  having  experience  in  congenital  heart  diseases.
All  implantations  of  Melody® valve  in  France  are  regis-
ered  in  an  on-going  prospective  observational  post  market
tudy  (www.clinicaltrials.gov  identiﬁer  NCT02023775).  This
tudy  was  requested  by  French  health  authorities  for  reim-
ursement  renewal,  to  maintain  reimbursement  for  PPVI  in
pproved  indication  in  France.
s
a
r
tre-procedural assessment
re-procedural  assessment  includes  a  complete  detailed  his-
ory  and  a  detailed  echocardiographic  assessment  (right
entricular  pressure,  dilation  and  function,  left  ventricular
ystolic  and  diastolic  function  [51]  and  associated  lesions).
ardio-pulmonary  testing  investigates  functional  perfor-
ance.  Myocardial  resonance  imaging  (MRI)  remains  the
old  standard  to  quantify  pulmonary  regurgitation  and  right
entricular  volumes  and  function.  Cardiac  tomography  is
seful  to  specify  the  spatial  relationship  between  the  RVOT
nd  the  surrounding  structures,  coronary  anatomy  at  risk
f  compression  but  unfortunately  is  not  accurate  to  predict
he  compression.  Most  of  the  centers  performed  therefore
nly  MRI  to  avoid  radiation  exposure.  PPVI  indication  can
e  discussed  during  a  medico-surgical  meeting  dedicated
o  congenital  heart  diseases  management.  The  PPVI  indica-
ion  is  retained  after  assessing  the  long-term  global  strategy
or  the  patient  with  surgeons  and  cardiologists.  A  particular
ttention  is  paid  on  the  absence  of  any  clinical  or  biological
igns  of  infections  before  the  PPVI.  Active  infection  of  any
ype  is  a  contra-indication  to  PPVI.  Dental  and  sinus  X-rays
nd  dental  referral  are  performed  before  the  PPVI  to  check
or  some  possible  sources  of  infection  similar  to  what  is  done
rior  to  surgical  valve  replacement.
ercutaneous pulmonary valve implantation
he  PPVI  is  generally  performed  under  general  anesthesia.  A
trict  asepsis  is  maintained  throughout  the  procedure.  Full
eparinization  and  antibiotics  are  performed  according  to
ocal  practice.  The  procedure  is  standardized  [49]  and  begins
ith  arterial  and  venous  access,  complete  hemodynamic
tudy  and  RVOT  angiographies  in  at  least  two  projections.  In
ase  of  RVOT  obstruction,  pre-dilation  of  the  landing  zone  is
erformed  with  high-pressure  balloon  to  see  if  a  RVOT  sub-
titute  can  be  opened  to  an  acceptable  diameter  for  PPVI
nd  to  check  for  coronary  compression.  Achieving  a  minimal
esidual  gradient  and  a  diameter  suitable  for  valve  implanta-
ion  are  uncommon  with  solely  balloon  dilation.  Most  of  the
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STranscatheter  pulmonary  valvulation:  Current  indications  an
patients  require  stent  implantation  to  achieve  these  goals.
A  successful  pre-dilation  decreases  the  risk  of  stent  mal-
position  and  residual  gradient  [38].  In  case  of  pulmonary
regurgitation,  low-pressure  balloon  inﬂation  is  performed
to  delineate  the  landing  zone,  its  length  and  diameter.  It
is  evaluated  whether  the  valve  will  be  safely  stabilized  in
the  dilated  conduit  without  embolization.  A  pre-stenting  is
performed  with  a  bare  metal  stent  or  a  covered  stent  in
case  of  extravasation  or  anticipated  conduit  fracture.  Pre-
stenting  is  continued  until  there  is  no  residual  signiﬁcant
obstruction  and  enough  rigidity  of  the  landing  zone  without
any  recoil,  any  compression  or  any  dynamic  motion.  Finally,
the  valve  is  crimped  on  the  delivery  system,  advanced  and
carefully  positioned  in  the  landing  zone.  Valve  post-dilation
at  the  valve  diameter  is  performed  if  there  is  a  residual
gradient  higher  than  20  mmHg  across  the  valve.  Usually  the
pre-stenting  and  the  PPVI  are  performed  within  the  same
procedure.  In  case  of  enlarged  RVOT  with  doubt  about  the
stability  of  the  pre-stented  landing  zone,  the  PPVI  may  be
postponed  for  some  weeks  to  allow  ingrowth  and  stabiliza-
tion  of  the  stent.
Post-procedural recommendation
Home  discharge  is  usually  feasible  within  one  to  two  days
after  the  PPVI  with  anti-platelet  medication  for  at  least
6  months.  Some  centers  recommend  long  life  aspirin  and
prevention  of  infective  endocarditis  [52,53].
Imaging modality
Success  rate  of  PPVI  is  higher  than  97%  in  most  series
[11,13,19,24,54].  The  success  of  PPVI  depends  on  the  pre-
cision  of  the  stents  and  valve  positioning.  It  remains  a
long  procedure  performed  under  ﬂuoroscopy  guidance  with
repeated  angiographies.  A  bi-plane  angiographic  system
decreases  the  need  for  repeated  iodine  contrast  injections
and  allows  bi-plane  imaging  without  moving  the  X-ray  tubes
[49].  But  the  procedure  can  be  performed  in  monoplane
system  with  excellent  results.  Modern  ﬂuoroscopic  angiog-
raphy  systems  also  permit  rendering  of  three-dimensional
volumetric  data  sets  using  rotational  angiography.  Along
with  magnetic  resonance  imaging  or  multi-detector-row
computed  tomography  datasets,  they  can  be  fused  with
live  ﬂuoroscopy  images  for  road-mapping  during  therapeu-
tic  procedures.  Three-dimensional  guidance  was  shown  to
simplify  catheter  manipulations  and  interventions,  to  allow
pre-selection  of  ideal  projection  angles  to  reduce  ﬂuoro-
scopic  time  and  the  number  of  control  angiographies  in
catheterization  of  congenital  heart  diseases  and  may  be
useful  for  PPVI  [55].  The  reel  beneﬁts  of  the  new  imaging
modalities  remain  to  be  demonstrated  in  this  indication.
Adverse events
During  the  ﬁrst  4200  PPVI,  eight  deaths  following  PPVI
were  recorded.  Most  of  them  were  related  to  coronary
compression  in  6  patients,  coronary  dissection  during  selec-
tive  coronary  angiography  in  one  patient  and  conduit  rupture
in  one  patient.  Acute  complication  rate  is  less  than  2%.  With
increasing  experience,  most  complications  could  potentially
M
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e  avoided  with  careful  patient  selection  and  appropriate
rocedural  technique.
oronary compression
n  some  patients  with  a surgically  implanted  RVPA  conduit
r  even  in  native  RVOT,  the  coronary  arteries  may  pass  in
lose  apposition.  Coronary  extrinsic  compression  following
he  PPVI  leads  to  acute  myocardial  infarction  [8,13,56,57].
re-procedural  imaging  by  cardiac  computed  tomography
r  magnetic  resonance  imaging  is  not  accurate  to  predict
he  risk.  Coronary  angiogram  with  simultaneously  a  balloon
nﬂated  in  the  landing  zone  in  the  RVOT  at  the  targeted
uter  valve  diameter  is  thus  recommended  prior  to  valve
mplantation  [49,58,59]. Aortic  root  angiogram  is  performed
rst  given  that  selective  coronary  angiogram  may  mask
roximal  compression.  Complementary  selective  coronary
ngiogram  is  performed  if  aortic  root  angiogram  is  incon-
lusive  (in  less  than  10%  of  the  patients  in  our  experience).
ncidence  of  coronary  compression  during  this  dynamic  test-
ng  ranges  from  4.7  to  6%  [58,59].  An  abnormal  coronary
rtery  anatomy  is  a  possible  risk  factor  [58].
VOT conduit rupture
artial  or  total  conduit  rupture  may  follow  balloon  pre-
ilation  especially  in  heavily  calciﬁed  homografts.  Most  of
he  time,  this  complication  is  managed  during  the  catheter-
zation  [13,49]. Covered  stents  are  used  to  conﬁne  the
xtravasation.  Rescue  surgery  is  sometimes  needed.
ulmonary artery injury
uide-wire  related  injuries  of  distal  pulmonary  artery
ranches  leading  to  bronchial  bleeding  or  hemothorax  man-
ged  medically  have  been  described  in  few  cases  [13].
ulmonary edema
cute  ﬂash  pulmonary  edema  following  PPVI  has  been
eported  [51]. This  rare  procedural  complication  may  be  due
o  the  sudden  increase  in  cardiac  output  that  overwhelms
he  left  ventricle.  An  unprepared  chronically  under-ﬁlled
eft  ventricle  and  a  reverse  Bernheim  effect  may  be  risk
actors.  In  high-risk  patients  with  abnormal  left  ventricle
iastolic  function,  priming  diuretics  treatment  before  the
rocedure  is  necessary.
nfective endocarditis
reat  concerns  were  raised  with  the  PPVI  (Melody®
nd  Edwards®)  following  infective  endocarditis  reports
8,13,18,52]. To  date  the  estimated  annualized  rate  of  a
rst  episode  of  infective  endocarditis  is  2.4%  per  patient-
ear  [53]. A  whole  review  is  dedicated  to  this  topic  in  this
pecial  issue.
tent fractureselody® valve  stent  fractures  following  PPVI  for  RVOT
bstruction  were  frequent  in  early  experience,  up  to  21%.
bsence  of  calciﬁcation,  non-conduit  outﬂow  tracts  and
6v
m
s
i
w
s
v
s
l
i
V
T
b
T
T
m
d
w
d
m
c
a
l
d
g
c
i
e
o
R
i
P
u
1
[
i
r
[
w
C
S
s
m
i
R
a
t
t
t
D
Y
i
R
[
[
[
[
[32  
alve  recoil  were  predisposing  factors  [54].  Prominent
echanical  stresses  on  the  RVOT  stent,  such  as  compres-
ion  between  the  anterior  chest  wall  and  heart,  appear  to
ncrease  stent  fracture  risk.  Melody® valve  fractures  were
ell  tolerated  but  led  to  an  increase  risk  of  valve  resteno-
is  [18].  New  stenting  is  often  necessary  associated  to  a
alve-in-valve  implantation  [60].  Increasing  experience  with
ystematic  pre-stenting  of  the  RVOT  [61]  and  choice  of  the
anding  zone  decreases  the  risk  of  stent  fractures  below  5%
n  last  reports  [8,18].
essel access injury
he  large  size  of  the  delivery  system  increases  the  risk  of
leeding  and  hematoma  at  the  vessel  access.
All  together  the  risk  of  complications  remains  very  low.
iming of pulmonary valve implantation
he  optimal  timing  of  dysfunctional  RVPA  conduit  replace-
ent  remains  controversial.  The  risk  of  irreversible
eterioration  of  right  ventricle  function  has  to  be  balanced
ith  the  risk  of  repeated  pulmonary  valve  replacement.  The
ecreased  procedural  morbidity  of  PPVI  compared  to  surgery
ay  allow  earlier  intervention  in  the  evolving  process  of
onduit  degeneration  to  reverse  the  effect  of  pressure
nd/or  volume  overload  on  the  right  ventricle.  However
ong-term  outcome  after  repeated  valve-in-valve  proce-
ures  is  unknown.  In  case  of  RVOT  obstruction,  there  is
rowing  evidence  for  the  efﬁciency  of  PPVI  on  clinical  out-
ome  and  ESC  guidelines  are  quite  precise  [40—43]. An  early
ntervention  is  necessary.  However,  stenting  alone  may  be  as
fﬁcient  and  may  delay  the  need  for  PPVI  [38].
Pulmonary  regurgitation  is  long  well  tolerated  and  impact
f  early  PPVI  in  these  cases  is  more  controversial  [40,42].
ather  than  the  severity  of  the  pulmonary  regurgitation,
t  is  the  degree  of  RV  dilation  that  should  prompt  the
PVI  indication  [19].  A  threshold  of  RV  end-diastolic  vol-
me  measured  by  myocardial  resonance  imaging  between
50—170  ml/m2 seems  the  limit  to  a  reversible  RV  dilation
62,63].  In  patients  with  severe  pulmonary  regurgitation,
ndications  of  revalvulation  continue  to  evolve  and  were
ecently  up-dated  including  MRI  and  rythmologic  criteria
64].  In  the  future,  the  longevity  of  the  percutaneous  valves
ill  impact  their  uses.
onclusion
ince  the  ﬁrst  implantation  in  2000,  PPVI  has  emerged  as  a
afe  and  efﬁcient  alternative  to  open-heart  surgery  with  less
orbidity.  It  is  now  considered  as  the  treatment  of  choice
n  patients  with  a  hemodynamically  signiﬁcant  dysfunctional
VPA  conduit  when  RVOT  anatomy  is  suitable.  New  devices
re  expected  to  extend  indication  in  enlarged  RVOT.  Long-
erm  follow-up  will  help  redeﬁne  PPVI  indication  compared
o  surgery  and  global  management  of  patients  with  dysfunc-
ional  RVOT.
[S. Hascoët  et  al.
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